Omeros Corporation (OMER) – Analysts’ Weekly Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Omeros Corporation (NASDAQ: OMER) in the last few weeks:

  • 10/27/2017 – Omeros Corporation had its “buy” rating reaffirmed by analysts at Maxim Group. They now have a $24.00 price target on the stock.
  • 10/25/2017 – Omeros Corporation was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros’ most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. “
  • 10/20/2017 – Omeros Corporation was given a new $24.00 price target on by analysts at Maxim Group. They now have a “buy” rating on the stock. They wrote, “Omeros announced successful treatment with OMS721 of a patient having both stem cell transplant-associated thrombotic microangiopathy (HCT-TMA) and graft vs. host disease (GvHD). The data were presented at the European Society for Blood and Marrow Transplantation (EBMT) Crash Course on Diagnosis and Treatment of Noninfectious Complications after HCT.””
  • 10/19/2017 – Omeros Corporation was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “strong-buy” rating. They now have a $22.00 price target on the stock. According to Zacks, “Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros’ most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. “

Shares of Omeros Corporation (NASDAQ:OMER) traded up 7.18% during trading on Monday, reaching $16.57. The company had a trading volume of 660,444 shares. Omeros Corporation has a 12-month low of $7.80 and a 12-month high of $27.09. The company’s market cap is $742.39 million. The firm has a 50-day moving average of $20.06 and a 200-day moving average of $19.47.

Omeros Corporation (NASDAQ:OMER) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.12. The company had revenue of $17.15 million during the quarter, compared to the consensus estimate of $14.63 million. During the same quarter last year, the firm earned ($0.32) EPS. The business’s revenue for the quarter was up 71.5% on a year-over-year basis. On average, equities research analysts anticipate that Omeros Corporation will post ($1.30) EPS for the current year.

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

What are top analysts saying about Omeros Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Omeros Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit